PPARγ Pro12Ala Polymorphism in HIV-1-Infected Patients with HAARTRelated Lipodystrophy

Peroxisome proliferator-activated receptor gamma (PPARγ) is involved in obesity and in some components of the metabolic syndrome in unselected population. To determine whether PPARγ genetic variants are associated with the risk of developing lipodystrophy and its associated metabolic disturbances in HIV-1-infected patients treated with HAART and to assess PPARγ mRNA expression in subcutaneous adipose tissue (SAT). The study group comprised 278 patients infected with HIV-1 and treated with antiretroviral drugs (139 with lipodystrophy and 139 without) and 105 uninfected controls (UC). The PPARγ Pro12Ala (C > G) single nucleotide polymorphism (SNP) was assessed using PCRRFLPs on white cell DNA. PPARγ mRNA expression in SAT was assessed in 38 patients (25 with lipodystrophy and 13 without) and in 21 UC by real-time PCR. Statistical analysis was based on Students T tests, 2 tests, Spearmans correlations tests and logistic regression tests. PPARγ Pro12Ala genotype distribution and allele frequencies were nonsignificantly different between both HIV-1-infected categories, lipodystrophy vs non-lipodystrophy (p = 0.9 and p = 0.87, respectively). Lipodystrophic patients harbouring the rare X/Ala genotype (Ala/Ala plus Pro/Ala) had significantly greater plasma total and LDL cholesterol levels compared with carriers of the common Pro/Pro genotype (p = 0.029 and p = 0.016, respectively) at univariate analyses. At multivariate analyses these associations were no longer significant. There was a near-significant decreased SAT PPARγ mRNA expression in patients with lipodystrophy compared to UC (p = 0.054). PPARγ Pro12Ala SNP has no effect on the risk of developing lipodystrophy in HIV-1-infected patients treated with HAART. PPARγ mRNA SAT expression appears decreased in lipodystrophy.

[1]  F. Villarroya,et al.  HIV-1 Infection and the PPARγ-Dependent Control of Adipose Tissue Physiology , 2008, PPAR research.

[2]  C. Mussini,et al.  Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy , 2008, AIDS.

[3]  B. Coll,et al.  The IL-6 system in HIV-1-infection and in HAART-related fat redistribution syndromes , 2008, AIDS.

[4]  G. Chrousos,et al.  Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. , 2008, Molecular endocrinology.

[5]  G. Behrens,et al.  HIV-therapy associated lipodystrophy: experimental and clinical evidence for the pathogenesis and treatment. , 2007, Endocrine, metabolic & immune disorders drug targets.

[6]  K. Kotani,et al.  Association of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene with small dense low-density lipoprotein in the general population. , 2007, Metabolism: clinical and experimental.

[7]  H. Worman,et al.  New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand , 2007, Journal of Medical Genetics.

[8]  M. Lombès,et al.  Mitochondrial Toxicity of Indinavir, Stavudine and Zidovudine Involves Multiple Cellular Targets in white and brown adipocytes , 2007, Antiviral therapy.

[9]  M. Kadakia,et al.  PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? , 2007, Journal of internal medicine.

[10]  R. Hegele,et al.  Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. , 2007, The Journal of clinical endocrinology and metabolism.

[11]  G. Palù,et al.  Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs , 2006, AIDS.

[12]  E. Schiffrin,et al.  Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. , 2006, Vascular pharmacology.

[13]  S. O’Rahilly,et al.  PPARγ and human metabolic disease , 2006 .

[14]  X. Matías-Guiu,et al.  Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV‐1‐infected patients: potential role in subcutaneous adipocyte apoptosis , 2005, European journal of clinical investigation.

[15]  P. Fischer-Posovszky,et al.  The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes. , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[16]  P. Amouyel,et al.  Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women. , 2005, Diabetes.

[17]  F. Villarroya,et al.  HIV-1 Infection Alters Gene Expression in Adipose Tissue, Which Contributes to HIV-1/Haart-Associated Lipodystrophy , 2005, Antiviral therapy.

[18]  R. Hegele.  Lessons from human mutations in PPARγ , 2005, International Journal of Obesity.

[19]  C. Mein,et al.  The common PPAR-γ2 Pro12Ala variant is associated with greater insulin sensitivity , 2004, European Journal of Human Genetics.

[20]  Johan Auwerx,et al.  Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. , 2004, Endocrine reviews.

[21]  J. Capeau,et al.  The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro , 2004, AIDS.

[22]  A. Sugawara,et al.  Transcription Suppression of Peroxisome Proliferator-Activated Receptor γ2 Gene Expression by Tumor Necrosis Factor α via an Inhibition of CCAAT/ Enhancer-binding Protein δ during the Early Stage of Adipocyte Differentiation , 2004 .

[23]  P. Amouyel,et al.  Impact of genetic variation of PPARγ in humans , 2004 .

[24]  J. Martínez,et al.  Estudios sobre la obesidad en genes candidatos , 2004 .

[25]  M. Dieudonné,et al.  In Vitro Suppression of the Lipogenic Pathway by the Nonnucleoside Reverse Transcriptase Inhibitor Efavirenz in 3T3 and Human Preadipocytes or Adipocytes* , 2004, Journal of Biological Chemistry.

[26]  X. Adiconis,et al.  Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. , 2004, Journal of lipid research.

[27]  B. Fromenty,et al.  Adipocytes Targets and Actors in the Pathogenesis of HIV-Associated Lipodystrophy and Metabolic Alterations , 2004, Antiviral therapy.

[28]  A. Hamsten,et al.  Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy , 2003, AIDS.

[29]  E. Boerwinkle,et al.  Pro12Ala of the peroxisome proliferator-activated receptor-gamma2 gene is associated with lower serum insulin levels in nonobese African Americans: the Atherosclerosis Risk in Communities Study. , 2003, Diabetes.

[30]  W. Rozenbaum,et al.  Altered Fat Differentiation and Adipocytokine Expression are Inter-Related and Linked to Morphological Changes and Insulin Resistance in HIV-1-Infected Lipodystrophic Patients , 2003, Antiviral therapy.

[31]  M. Laakso,et al.  Effect of the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue of massively obese subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[32]  Kunihiro Matsumoto,et al.  Cytokines suppress adipogenesis and PPAR-γ function through the TAK1/TAB1/NIK cascade , 2003, Nature Cell Biology.

[33]  A. Carr.  An objective case definition of lipodystrophy in HIV-infected adults: a case-control study , 2003, The Lancet.

[34]  M. Laakso,et al.  Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. , 2002, European journal of endocrinology.

[35]  M. Stumvoll,et al.  The Peroxisome Proliferator-Activated Receptor-γ2 Pro12Ala Polymorphism , 2002 .

[36]  J. Schölmerich,et al.  Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 (PPARgamma2) is associated with higher levels of total cholesterol and LDL-cholesterol in male caucasian type 2 diabetes patients. , 2002, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[37]  W. Rozenbaum,et al.  Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance , 2002, The Lancet.

[38]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[39]  C. Vigouroux,et al.  The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. , 2001, Diabetes.

[40]  C. Flexner,et al.  Suppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease Inhibitors* , 2000, The Journal of Biological Chemistry.

[41]  M. Kasuga,et al.  Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. , 2000, Biochemical and biophysical research communications.

[42]  J. Auwerx,et al.  Impact of the Peroxisome Proliferator Activated Receptor γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus , 2000, International Journal of Obesity.

[43]  N. Christeff,et al.  Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. , 1999, AIDS.

[44]  J. Vamecq,et al.  Medical significance of peroxisome proliferator-activated receptors , 1999, The Lancet.

[45]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[46]  J. Auwerx,et al.  A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. , 1998, Human molecular genetics.

[47]  C. Vigouroux,et al.  HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. , 2005, Biochimie.

[48]  R. D'Agostino,et al.  Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.